---
document_datetime: 2023-09-21 19:35:38
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vantobra-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: vantobra-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.205383
conversion_datetime: 2025-12-23 21:46:53.437127
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## VANTOBRA

Procedural steps taken and scientific  information after the authorisation

| Application number   | Scope                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------|
| IA IN/0011           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site product        | 20/10/2017                          | n/a                                            |                                  |                                   |
| PSUSA/10370 /201703  | Periodic Safety Update EU Single assessment - tobramycin (nebuliser solution) (centrally authorised product only) | 28/09/2017                          | n/a                                            |                                  | PRAC Recommendation - maintenance |

1 Notifications are issued for type I variations and A rticle 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). O pinions are issued for all other procedures.

2  A  C ommission decision (C D) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of A rticle 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), A nnex II, Labelling, PL (Package Leaflet).

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0010              | Minor change in labelling or package leaflet not connected with the SPC (A rt.61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                | 21/09/2017   |        | PL                                |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|-----------------------------------|
| PSUSA/10370 /201609 | Periodic Safety Update EU Single assessment - tobramycin (nebuliser solution) (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                               | 06/04/2017   | n/a    | PRAC Recommendation - maintenance |
| IA IN/0007/G        | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits ofan AS,starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.III.1.a.3 - Submission of a new/updated or deletion of Ph.Eur. Certificate of Suitability to the relevant Ph.Eur.Monograph - Newcertificate from a new manufacturer (replacement or addition)                          | 28/11/2016   | n/a no | longer                            |
| N/0006              | Inclusion of the 2D barcode on the label of the outer carton and reduction of the label text on the printed pouch label.In addition, the MAHupdated the lis t of local representatives at the end of the Package Leaflet to include all the memberstates in accordance with the QRD guidance and the MAH revised the contact details of the local representatives for NL,UK,ES and PT. Minor change in labelling or package leaflet not connected with the SPC (A rt.61.3 Notification) product | 24/10/2016   |        | Labelling and PL                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10370 /201603   | Periodic Safety Update EU Single assessment - tobramycin (nebuliser solution) (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 29/09/2016   | n/a        | PRAC Recommendation - maintenance   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| IA/0005               | B.II.b.2.a - Change to importer,batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/09/2016   | n/a        |                                     |
| IA/0004               | B.II.b.2.a - Change to importer,batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/08/2016   | n/a        | longer                              |
| PSUSA/10370 /201509   | Periodic Safety Update EU Single assessment - tobramycin (nebuliser solution) (centrally authorised product only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/04/2016   | n/a no     | PRAC Recommendation - maintenance   |
| II/0001/G             | This was an application for a group of variations. B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceuticalforms manufactured by complex manufacturing processes B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place,except batch product | 24/09/2015   | 30/09/2016 | SmPC, and                           |

<div style=\"page-break-after: always\"></div>

release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site Medicinal product no longer authorised